Retinal Biologics Market - Global Industry Analysis

Retinal Biologics Market By Drug Class (TNF-a Inhibitor and VEGF-A Antagonist), By Indication (Diabetic Retinopathy, Macular Degeneration, Uveitis, Diabetic Macular Edema, and Others), and by Distribution Channel (Retail Sales and Institutional Sales): Global Market Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 16-Sep-2019 Category: Pharmaceutical Report Format : PDF Pages: 120 Report Code: ZMR-4744 Status : Published

Global retinal biologics market is expected to generate around USD 28,015 million by 2025, at a CAGR of 11.5% between 2019 and 2025. The worldwide escalation of ophthalmic disorders, due to aging, is the prime factor driving the retinal biologics market globally.

Description

The report covers a forecast and an analysis of the global retinal biologics market on a global and regional level. The study provides historical data from 2017 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the global retinal biologics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the global retinal biologics market on a global level.

In order to give the users a comprehensive view of the global retinal biologics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Retinal Biologics Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the global retinal biologics market is segmented based on drug class, indication, distribution channel, and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some key players of the retinal biologics market are Janssen Biotech, Alimera Sciences, F. Hoffmann-La Roche, Ocular Therapeutix, Genzyme Corporation, UCBCares, AbbVie, Allergan, Swedish Orphan Biovitrum, Genentech, Bristol-Myers Squibb, and Bausch & Lomb.

This report segments the global retinal biologics market into:

Global Retinal Biologics Market: Drug Class Analysis

  • TNF-α Inhibitor
  • VEGF-A Antagonist

Global Retinal Biologics Market: Indication Analysis

  • Diabetic Retinopathy
  • Macular Degeneration
  • Uveitis
  • Diabetic Macular Edema
  • Others

Global Retinal Biologics Market: Distribution Channel Analysis

  • Retail Sales
    • Mail Order Pharmacies
    • Retail Pharmacies
  • Institutional Sales
    • Hospitals
    • Specialty Clinics

Global Retinal Biologics Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Retinal Biologics Market, 2017-2025 (USD Million)
    • 2.2. Global Retinal Biologics Market: Snapshot
  •  
  • Chapter 3. Global Retinal Biologics Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of retinal disorders
      • 3.2.2. Technical advancement for ophthalmic drugs
      • 3.2.3. Rising Geriatric Population
      • 3.2.4. Favorable reimbursement policies in developed regions
    • 3.3. Market Restraints
      • 3.3.1. Introduction to alternate therapies
      • 3.3.2. High Treatment Cost
    • 3.4. Opportunities
      • 3.4.1. Strategic alliances formed by the market players
      • 3.4.2. Increasing awareness about the latest development
      • 3.4.3. Opportunity from developing regions
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Drug Class
      • 3.6.2. Market attractiveness analysis, by Indication
      • 3.6.3. Market attractiveness analysis, by Distribution Channel
      • 3.6.4. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Retinal Biologics Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Retinal Biologics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Retinal Biologics Market - Drug Class Analysis
    • 5.1. Global Retinal Biologics Market: Drug Class overview
      • 5.1.1. Global Retinal Biologics Market Revenue, by Drug Class, 2018 and 2025
    • 5.2. TNF-α inhibitor
      • 5.2.1. Global Retinal Biologics market for TNF-α inhibitor, 2017-2025 (USD Million)
    • 5.3. VEGF-A antagonist
      • 5.3.1. Global Retinal Biologics market for VEGF-A antagonist, 2017-2025 (USD Million)
  •  
  • Chapter 6. Global Retinal Biologics Market - Indication Analysis
    • 6.1. Global Retinal Biologics Market: Indication overview
      • 6.1.1. Global Retinal Biologics Market Revenue, by Indication, 2018 and 2025
    • 6.2. Diabetic Retinopathy
      • 6.2.1. Global Retinal Biologics market for Diabetic Retinopathy, 2017-2025 (USD Million)
    • 6.3. Macular Degeneration
      • 6.3.1. Global Retinal Biologics market for Macular Degeneration, 2017-2025 (USD Million)
    • 6.4. Uveitis
      • 6.4.1. Global Retinal Biologics market for Uveitis, 2017-2025 (USD Million)
    • 6.5. Diabetic Macular Edema
      • 6.5.1. Global Retinal Biologics market for Diabetic Macular Edema, 2017-2025 (USD Million)
    • 6.6. Others
      • 6.6.1. Global Retinal Biologics market for Others, 2017-2025 (USD Million)
  •  
  • Chapter 7. Global Retinal Biologics Market - Distribution Channel Analysis
    • 7.1. Global Retinal Biologics Market: Distribution Channel
      • 7.1.1. Global Retinal Biologics Market Revenue, by Distribution Channel, 2018 and 2025
    • 7.2. Retail Sales
      • 7.2.1. Global Retinal Biologics market for Retail Sales, 2017-2025 (USD Million)
    • 7.3. Institutional Sales
      • 7.3.1. Global Retinal Biologics market for Institutional Sales, 2017-2025 (USD Million)
  •  
  • Chapter 8. Global Retinal Biologics Market - Regional Analysis
    • 8.1. Global Retinal Biologics Market: Regional Overview
      • 8.1.1. Global Retinal Biologics Market Revenue, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
      • 8.2.2. North America Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
      • 8.2.3. North America Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.4. The U.S.
        • 8.2.4.1. The U.S. Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.2.4.2. The U.S. Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.2.4.3. The U.S. Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.2.5. Rest of North America
        • 8.2.5.1. Rest of North America Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.2.5.2. Rest of North America Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.2.5.3. Rest of North America Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
      • 8.3.2. Europe Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
      • 8.3.3. Europe Retinal Biologics Market Revenue, by End -User, 2017-2025 (USD Million)
      • 8.3.4. UK
        • 8.3.4.1. UK Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.3.4.2. UK Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.3.4.3. UK Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.5. Germany
        • 8.3.5.1. Germany Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.3.5.2. Germany Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.3.5.3. Germany Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.3.6.2. France Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.3.6.3. France Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.3.7. Rest of Europe
        • 8.3.7.1. Rest of Europe Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.3.7.2. Rest of Europe Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.3.7.3. Rest of Europe Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
      • 8.4.2. Asia Pacific Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
      • 8.4.3. Asia Pacific Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.4. China
        • 8.4.4.1. China Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.4.4.2. China Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.4.4.3. China Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.5. Japan
        • 8.4.5.1. Japan Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.4.5.2. Japan Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.4.5.3. Japan Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.6. India
        • 8.4.6.1. India Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.4.6.2. India Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.4.6.3. India Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.4.7. Rest of Asia Pacific
        • 8.4.7.1. Rest of Asia Pacific Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.4.7.2. Rest of Asia Pacific Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.4.7.3. Rest of Asia Pacific Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
      • 8.5.2. Latin America Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
      • 8.5.3. Latin America Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.4. Brazil
        • 8.5.4.1. Brazil Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.5.4.2. Brazil Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.5.4.3. Brazil Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
      • 8.5.5. Rest of Latin America
        • 8.5.5.1. Rest of Latin America Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
        • 8.5.5.2. Rest of Latin America Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
        • 8.5.5.3. Rest of Latin America Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Retinal Biologics Market Revenue, by Drug Class, 2017-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Retinal Biologics Market Revenue, by Indication, 2017-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Retinal Biologics Market Revenue, by Distribution Channel, 2017-2025 (USD Million)
  •  
  • Chapter 9. Company Profile
    • 9.1. Janssen Biotech
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Drug Class portfolio
      • 9.1.4. Business strategy
      • 9.1.5. Recent developments
    • 9.2. Alimera Sciences
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Drug Class portfolio
      • 9.2.4. Business strategy
      • 9.2.5. Recent developments
    • 9.3. F. Hoffmann-La Roche
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Drug Class portfolio
      • 9.3.4. Business strategy
      • 9.3.5. Recent developments
    • 9.4. Ocular Therapeutix
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Drug Class portfolio
      • 9.4.4. Business strategy
      • 9.4.5. Recent developments
    • 9.5. Genzyme Corporation
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Drug Class portfolio
      • 9.5.4. Business strategy
      • 9.5.5. Recent developments
    • 9.6. UCBCares
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Drug Class portfolio
      • 9.6.4. Business strategy
      • 9.6.5. Recent developments
    • 9.7. AbbVie
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Drug Class portfolio
      • 9.7.4. Business strategy
      • 9.7.5. Recent developments
    • 9.8. Allergan
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Drug Class portfolio
      • 9.8.4. Business strategy
      • 9.8.5. Recent developments
    • 9.9. Swedish Orphan Biovitrum
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Drug Class portfolio
      • 9.9.4. Business strategy
      • 9.9.5. Recent developments
    • 9.10. Genentech
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Drug Class portfolio
      • 9.10.4. Business strategy
      • 9.10.5. Recent developments
    • 9.11. Bristol-Myers Squibb
      • 9.11.1. Overview
      • 9.11.2. Financials
      • 9.11.3. Drug Class portfolio
      • 9.11.4. Business strategy
      • 9.11.5. Recent developments
    • 9.12. Bausch & Lomb
      • 9.12.1. Overview
      • 9.12.2. Financials
      • 9.12.3. Drug Class portfolio
      • 9.12.4. Business strategy
      • 9.12.5. Recent developments

Table Of Figures

List of Figures 

1. Market Research Process
2. Market Research Methodology
3. Global Retinal Biologics Market Revenue, 2017–2025 (USD Million)
4. Porter’s Five Forces Analysis
5. Global Retinal Biologics market attractiveness analysis, by Drug Class
6. Global Retinal Biologics market attractiveness analysis, by Indication
7. Global Retinal Biologics market attractiveness analysis, by Distribution Channel
8. Global Retinal Biologics Market: market attractiveness analysis, by region
9. Company market share analysis, 2019
10. Global Retinal Biologics market revenue share by Drug Class, 2018 and 2025
11. Global Retinal Biologics market revenue share by TNF-α inhibitor, 2017–2025 (USD Million)
12. Global Retinal Biologics market revenue share by VEGF-A antagonist, 2017–2025 (USD Million)
13. Global Retinal Biologics market revenue share by Indication, 2018 and 2025 
14. Global Retinal Biologics market revenue share by Diabetic Retinopathy, 2017–2025 (USD Million)
15. Global Retinal Biologics market revenue share by Macular Degeneration, 2017–2025 (USD Million)
16. Global Retinal Biologics market revenue share by Uveitis, 2017–2025 (USD Million)
17. Global Retinal Biologics market revenue share by Diabetic Macular Edema, 2017–2025 (USD Million)
18. Global Retinal Biologics market revenue share by Others, 2017–2025 (USD Million)
19. Global Retinal Biologics market revenue share by Distribution Channel, 2018 and 2025
20. Global Retinal Biologics market revenue share by Retail Sales, 2017–2025 (USD Million)
21. Global Retinal Biologics market revenue share by Institutional Sales, 2017–2025 (USD Million)


Table Of Tables

List of Tables

1. Global Retinal Biologics Market: Snapshot                                                                                                                        
2. Drivers of the Global Retinal Biologics Market: Impact Analysis 
3. Restraints of the Global Retinal Biologics Market: Impact Analysis
4. North America Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
5. North America Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
6. North America Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
7. The U.S. Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
8. The U.S. Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
9. The U.S. Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
10. Rest of North America Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
11. Rest of North America Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
12. Rest of North America Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
13. Europe Global Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
14. Europe Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
15. Europe Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
16. U.K. Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
17. U.K. Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
18. U.K. Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
19. Germany Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
20. Germany Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
21. Germany Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
22. France Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
23. France Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
24. France Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
25. Rest of Europe Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
26. Rest of Europe Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
27. Rest of Europe Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
28. Asia Pacific Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
29. Asia Pacific Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
30. Asia Pacific Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
31. China Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
32. China Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
33. China Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
34. Japan Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
35. Japan Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
36. Japan Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
37. India Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
38. India Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
39. India Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
40. Rest of Asia Pacific Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
41. Rest of Asia Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
42. Rest of Asia Pacific Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
43. Latin America Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
44. Latin America Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
45. Latin America Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
46. Brazil Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
47. Brazil Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
48. Brazil Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
49. Rest of Latin America Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million) 
50. Rest of Latin America Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
51. Rest of Latin America Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)
52. The Middle East and Africa Retinal Biologics Market Revenue, by Drug Class, 2017–2025 (USD Million)
53. The Middle East and Africa Retinal Biologics Market Revenue, by Indication, 2017–2025 (USD Million)
54. The Middle East and Africa Retinal Biologics Market Revenue, by Distribution Channel, 2017–2025 (USD Million)

Methodology

Free Analysis

The retina is a sensitive and delicate part of the human eye, which receives and processes light and converts it into neural signals and forwards them to the brain for performing visual activities. Retinal disorders include macular degeneration related to age, infectious retinitis, macular edema, diabetic retinopathy, macular hole, retinoblastoma, retinal degeneration, uveitis, and retinoschisis.

The worldwide escalation of ophthalmic disorders, due to aging, is the prime factor driving the retinal biologics market globally. The development of several new products in the form of drug-releasing implants and biologics due to the consistent efforts for developing better treatment options are further propelling the market for retinal biologics. The developments in the biologics in the field of ophthalmology have completely changed the way patients are treated in the current times. However, the limited availability of the biologics, adverse effects of biologics, strict regulatory requirements associated with biologics approval, and the lack of accessibility for biologics and effective drugs due to the high prices may hamper the market for retinal biologics in the future.

Global Retinal Biologics Market

The retinal biologics market is fragmented based on drug class, indication, and distribution channel. By drug class, the market includes TNF-α inhibitor and VEGF-An antagonist. On the basis of indication, the retinal biologics market comprises diabetic macular edema, macular degeneration, diabetic retinopathy, uveitis, and others. The distribution channel segment includes retail sales and institutional sales. The retail sales segment includes mail order and retail pharmacies. The institutional sales segment is bifurcated into specialty clinics and hospitals. The institutional sales segment accounted for the largest share in the retinal biologics market in 2018.

In Europe, rising incidences retinal disorders is fuelling the regional retinal biologics demand. This, in turn, is supporting the region’s retinal biologics market. The cases of retinal diseases in the Asia Pacific region were less as compared to other regions. However, this figure is likely to increase in the upcoming years, which will support the region’s retinal biologics market. Diabetes plays a significant role in retinal disease treatment. The rising rate of diabetes in the developing nations, due to unhealthy habits and inactive lifestyle, will also boost the retinal biologics market in the region.

Some key players of the retinal biologics market are Bristol-Myers Squibb, Janssen Biotech, Alimera Sciences, F. Hoffmann-La Roche, Ocular Therapeutix, Genzyme Corporation, UCBCares, AbbVie, Allergan, Swedish Orphan Biovitrum, Bausch & Lomb, and Genentech.

Choose License Type

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed